In this on-demand webcast, an expert discusses the mechanism of action of antibody drug conjugates (ADCs) and how those directed at HER2, HER3, and TROP2 are being used to manage various solid tumors.
- Provider:Partners for Advancing Clinical Education (PACE)
- Activity Link: https://clinicaloptions.com/activities/oncology/understanding-and-differentiating-adcs-in-solid-tumors/64459/info
- Start Date: 2024-12-03 06:00:00
- End Date: 2024-12-03 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 31250.0 - Is Kind Support: False Source: Gilead Sciences, Inc. - Amount: 31250.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest